Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SOPHiA GENETICS (SOPH) Operating Leases (2020 - 2025)

Historic Operating Leases for SOPHiA GENETICS (SOPH) over the last 6 years, with Q3 2025 value amounting to $13.2 million.

  • SOPHiA GENETICS's Operating Leases fell 1778.1% to $13.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.2 million, marking a year-over-year decrease of 1778.1%. This contributed to the annual value of $14.6 million for FY2024, which is 682.7% down from last year.
  • As of Q3 2025, SOPHiA GENETICS's Operating Leases stood at $13.2 million, which was down 1778.1% from $13.9 million recorded in Q2 2025.
  • SOPHiA GENETICS's 5-year Operating Leases high stood at $16.7 million for Q4 2022, and its period low was $2.3 million during Q2 2021.
  • In the last 5 years, SOPHiA GENETICS's Operating Leases had a median value of $14.6 million in 2024 and averaged $13.7 million.
  • As far as peak fluctuations go, SOPHiA GENETICS's Operating Leases skyrocketed by 53993.09% in 2022, and later crashed by 1778.1% in 2025.
  • Quarter analysis of 5 years shows SOPHiA GENETICS's Operating Leases stood at $13.1 million in 2021, then rose by 28.21% to $16.7 million in 2022, then decreased by 6.39% to $15.7 million in 2023, then fell by 6.83% to $14.6 million in 2024, then decreased by 9.72% to $13.2 million in 2025.
  • Its Operating Leases stands at $13.2 million for Q3 2025, versus $13.9 million for Q2 2025 and $14.5 million for Q1 2025.